The traditional biopharma approach focused primarily on physician detailing and securing favorable payer contracts, has become inadequate in today’s market.
John Strapp
Advertisement
Articles by John Strapp
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Nimbus Therapeutics and Eli Lilly Enter $1.3 Billion License Agreement and Research Collaboration for Oral Obesity Treatments
2
Amgen Acquires Dark Blue Therapeutics in $840 Million Transaction
3
Novo Nordisk’s Wegovy Pill Becomes First Oral GLP-1 Available in U.S.
4
The Real Value Equation: How Humans and AI Create and Destroy Value in Pharma
5